Chronic lymphocytic leukemia treatment algorithm 2018
Open Access
- 3 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (10), 1-10
- https://doi.org/10.1038/s41408-018-0131-2
Abstract
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as ibrutinib, idelalisib, and venetoclax), and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Each of these treatments is associated with a unique toxicity profile; in the absence of randomized data, the choice of one type of treatment over another depends on the co-morbidities of the patient. Chemoimmunotherapy still plays an important role in the management of previously untreated CLL patients, particularly among young fit patients who have standard risk FISH profile and mutated IGHV genes. Richter’s transformation of CLL remains a difficult complication to treat, although therapy with programmed death 1 inhibitors such as pembrolizumab and nivolumab has shown impressive responses in a subset of patients. Our ability to risk stratify CLL patients continues to evolve; the CLL-International Prognostic Index (CLL-IPI) is the best validated tool in predicting time to first therapy among previously untreated patients. This review summarizes the current approach to risk stratification and management of CLL patients.Keywords
This publication has 84 references indexed in Scilit:
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaBlood, 2013
- The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trialBlood, 2013
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaBlood, 2012
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- NOTCH1 PEST domain mutation is an adverse prognostic factor in B‐CLLBritish Journal of Haematology, 2010
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaBlood, 2008
- CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialBritish Journal of Haematology, 2008
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Serum β2-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and ImmunocytomaLeukemia & Lymphoma, 1996